Announcement on Voluntary Disclosure of the Inclusion of ZG006 for Injection for the Treatment of Advanced Neuroendocrine Carcinoma in the Publicity List for Breakthrough Therapy Designation

About this update from Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A

Announcement on Voluntary Disclosure of the Inclusion of ZG006 for Injection for the Treatment of Advanced Neuroendocrine Carcinoma in the Publicity List for Breakthrough Therapy DesignationThe abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A